EcoDrugPlus

Adrenoceptor Alpha 2b

Ensembl ID : ENSOKIG00005029442
Gene Symbol: ADRA2B
1 Cross references
143 Possible Orthologues:

Adrenoceptor Alpha 2b

Ensembl ID : ENSOKIG00005018453
Gene Symbol: ADRA2B
1 Cross references
169 Possible Orthologues:

Adrenoceptor Alpha 2c

Ensembl ID : ENSOKIG00005009881
Gene Symbol: ADRA2C
1 Cross references
151 Possible Orthologues:

Adrenoceptor Alpha 2c

Ensembl ID : ENSOKIG00005025378
Gene Symbol: ADRA2C
1 Cross references
151 Possible Orthologues:

Adrenoceptor Alpha 2c

Ensembl ID : ENSOKIG00005031361
Gene Symbol: ADRA2C
3 Cross references
159 Possible Orthologues:

Adrenoceptor Alpha 2c

Ensembl ID : ENSOKIG00005028435
Gene Symbol: ADRA2C
1 Cross references
159 Possible Orthologues:

Adrenoceptor Beta 2

Ensembl ID : ENSOKIG00005040557
Gene Symbol: ADRB2
1 Cross references
189 Possible Orthologues:

Adrenoceptor Beta 3b

Ensembl ID : ENSOKIG00005003858
Gene Symbol: ADRB3B
1 Cross references
144 Possible Orthologues:

Aldo-Keto Reductase Family 1 Member B

Ensembl ID : ENSOKIG00005050735
Gene Symbol: AKR1B1
1 Cross references
266 Possible Orthologues:

Aldo-Keto Reductase Family 1 Member B

Ensembl ID : ENSOKIG00005010163
Gene Symbol: AKR1B1
3 Cross references
341 Possible Orthologues:

Aldo-Keto Reductase Family 1 Member B

Ensembl ID : ENSOKIG00005005941
Gene Symbol: AKR1B1
1 Cross references
330 Possible Orthologues:

Aldo-Keto Reductase Family 1 Member B1

Ensembl ID : ENSOKIG00005010238
Gene Symbol: LOC109896780
3 Cross references
334 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).